35.04
Atricure Inc stock is traded at $35.04, with a volume of 1.65M.
It is up +6.18% in the last 24 hours and up +23.90% over the past month.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
See More
Previous Close:
$33.00
Open:
$33.69
24h Volume:
1.65M
Relative Volume:
1.81
Market Cap:
$1.77B
Revenue:
$534.53M
Net Income/Loss:
$-11.45M
P/E Ratio:
-145.33
EPS:
-0.2411
Net Cash Flow:
$48.28M
1W Performance:
+0.26%
1M Performance:
+23.90%
6M Performance:
-10.31%
1Y Performance:
+16.14%
Atricure Inc Stock (ATRC) Company Profile
Name
Atricure Inc
Sector
Industry
Phone
513-755-4100
Address
7555 INNOVATION WAY, MASON, OH
Compare ATRC vs ISRG, BDX, ALC, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
ATRC
Atricure Inc
|
35.04 | 1.77B | 534.53M | -11.45M | 48.28M | -0.2411 |
|
ISRG
Intuitive Surgical Inc
|
337.50 | 120.92B | 11.03B | 3.16B | 3.22B | 8.7251 |
|
BDX
Becton Dickinson Co
|
156.36 | 43.08B | 21.37B | 1.41B | 3.07B | 3.9437 |
|
ALC
Alcon Inc
|
67.91 | 33.12B | 10.63B | 819.00M | 1.59B | 1.6577 |
|
MDLN
Medline Inc
|
38.75 | 32.77B | 29.14B | 1.07B | 1.05B | 1.1956 |
|
RMD
Resmed Inc
|
195.27 | 28.33B | 5.54B | 1.52B | 1.74B | 10.37 |
Atricure Inc Stock (ATRC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-18-26 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-11-26 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-17-24 | Resumed | JP Morgan | Overweight |
| Apr-23-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-23-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-29-23 | Initiated | UBS | Buy |
| Aug-05-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-18-20 | Reiterated | Needham | Buy |
| Nov-06-20 | Reiterated | Needham | Buy |
| Apr-07-20 | Initiated | Oppenheimer | Outperform |
| Feb-06-20 | Initiated | BTIG Research | Buy |
| Jan-24-20 | Reiterated | Needham | Buy |
| Aug-13-19 | Downgrade | Northland Capital | Outperform → Market Perform |
| Apr-12-19 | Initiated | JP Morgan | Overweight |
| Oct-04-18 | Reiterated | Needham | Buy |
| Aug-02-18 | Reiterated | Needham | Buy |
| Aug-02-18 | Reiterated | Stifel | Buy |
| Jun-18-18 | Reiterated | Needham | Buy |
| Apr-27-18 | Reiterated | Needham | Buy |
| Jan-16-18 | Reiterated | Needham | Buy |
| Nov-02-17 | Reiterated | Needham | Buy |
| Jul-28-17 | Reiterated | Needham | Buy |
| May-30-17 | Resumed | Piper Jaffray | Overweight |
| Jun-30-16 | Resumed | JMP Securities | Mkt Outperform |
| Oct-28-15 | Reiterated | Needham | Buy |
| Oct-06-15 | Reiterated | Canaccord Genuity | Buy |
| Oct-06-15 | Reiterated | Needham | Buy |
View All
Atricure Inc Stock (ATRC) Latest News
AtriCure Reports Second Quarter 2026 Financial Results - BioSpace
AtriCure revenue up 12.8% to USD 153.6M in Q2 2026 - Medical Buyer
AtriCure Inc (ATRC) Q2 2026 Earnings Call Highlights: Strong Rev - GuruFocus
AtriCure Inc (ATRC) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and Profitability ... - Yahoo Finance
AtriCure (ATRC) Reports Strong Q2 2026 Results with Revenue Grow - GuruFocus
AtriCure Releases Q2 2026 Financial Results - AlphaStreet
AtriCure Q2 Swings to Adjusted Earnings, Revenue Rises - Moomoo
Transcript : AtriCure, Inc., Q2 2026 Earnings Call, Jul 23, 2026 - marketscreener.com
AtriCure (ATRC) Reports Q2 Earnings: What Key Metrics Have to Say - Yahoo Finance
AtriCure Q2 Earnings Call Highlights - TradingView
Is AtriCure Inc (ATRC) Undervalued After Q2 Earnings Beat? EPS $0.18 on Revenue of $153.6M -- GF Score 78/100 - GuruFocus
Earnings call transcript: AtriCure tops Q2 2026 estimates, shares fall after hours - Investing.com
AtriCure Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
AtriCure (ATRC) Q2 Earnings and Revenues Top Estimates - Yahoo Finance
AtriCure surges 3% on earnings beat and raised guidance By Investing.com - Investing.com South Africa
AtriCure (NASDAQ:ATRC) Profitability Surge Drives After-Hours Rally Despite Inline Revenue - ChartMill
ATRICURE ($ATRC) Releases Q2 2026 Earnings, Stock Rises - Quiver Quantitative
(ATRC) AtriCure Expects 2026 Adjusted EPS Range $0.24-$0.32, vs. FactSet Est of $0.12 - marketscreener.com
(ATRC) AtriCure Expects 2026 Revenue Range $602M-$610M, vs. FactSet Est of $604.6M - marketscreener.com
AtriCure 2Q Net $8.96M >ATRC - Moomoo
AtriCure: Q2 Earnings Snapshot - The Daily Independent
Earnings Flash (ATRC) AtriCure, Inc. Reports Q2 Revenue $153.6M, vs. FactSet Est of $151.8M - marketscreener.com
Earnings Flash (ATRC) AtriCure, Inc. Posts Q2 Adjusted EPS $0.18 per Share, vs. FactSet Est of $0.00 - marketscreener.com
AtriCure reports Q2 2026 revenue $153.6M, net income $9.0M and adjusted EBITDA $27.3M - TradingView
BRIEF-AtriCure Q2 Adjusted EPS USD 0.18 Vs. IBES Estimate USD 0 - TradingView
Press Release: AtriCure Reports Second Quarter 2026 Financial Results - Moomoo
AtriCure set to report earnings as competitive threat looms By Investing.com - Investing.com Canada
AtriCure set to report earnings as competitive threat looms - Investing.com
Citizens reiterates AtriCure stock rating on product growth outlook - Investing.com UK
Hybrid AF therapy offers new rhythm care as AtriCure stock trades down from last week - Traders Union
Citizens reiterates AtriCure stock rating on product growth outlook By Investing.com - Investing.com Canada
AtriCure stock consolidates above key averages amid strong trend signals and recent care milestone - Traders Union
AtriCure unveils AtriClip Mini as AtriCure stock trades up to 35.16 amid bullish momentum - Traders Union
AtriCure (ATRC) Proxy filing Summary - Quartr
AtriCure (ATRC) Declines 1.88%, Approaches Key Support at $33.2Momentum Breakout Ideas - dars.gov.et
AtriCure (ATRC) Edges Lower Amid Mixed Market Sentiment — Key Support and Resistance Levels in FocusDividend Arbitrage - dars.gov.et
(ATRC) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Needham Initiates AtriCure(ATRC.US) With Buy Rating, Announces Target Price $45 - Moomoo
Needham Maintains AtriCure(ATRC.US) With Buy Rating, Maintains Target Price $45 - Moomoo
AtriCure (ATRC) Investor Day 2025 Summary - Quartr
Is AtriCure's (ATRC) Russell 2000 Defensive Debut Quietly Reframing Its Risk‑Reward Profile? - simplywall.st
AtriCure (ATRC) Jumps Nearly 7% as Healthcare Sector Sees Renewed InterestTotal Put Call - dars.gov.et
AtriCure to announce second quarter 2026 financial results - scanx.trade
AtriCure to Announce Second Quarter 2026 Financial Results - BioSpace
Form 4 AtriCure Inc For: 2 July By Investing.com - Investing.com Canada
AtriCure (ATRC) CEO adds 636 shares through 2018 Employee Stock Purchase Plan - Stock Titan
AtriCure, Inc. (ATRC) CSO acquires 636 ESPP shares at discount - Stock Titan
AtriCure (ATRC) CLO acquires 636 shares in ESPP purchase - Stock Titan
AtriCure (ATRC) COO adds ESPP shares in routine acquisition - Stock Titan
AtriCure (ATRC) CTO adds shares through discounted Employee Stock Purchase Plan - Stock Titan
AtriCure | 4: Statement of changes in beneficial ownership of securities-Officer Privitera Salvatore - Moomoo
Atricure Inc Stock (ATRC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):